Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2009

01-12-2009 | Introduction

Controversies in Breast Cancer 2009

Author: William R Miller

Published in: Breast Cancer Research | Special Issue 3/2009

Login to get access

Excerpt

This supplement represents the proceedings of Controversies in Breast Cancer held in Edinburgh, 7 to 8 September 2009. This meeting was the fourth in what has now become a series of meetings. Although many of the subjects and faculty members were different from those in previous meetings, the objectives and format were similar to those held before. Essentially a faculty of recognised international experts had assembled to debate controversial issues with a common theme relating to the natural history and treatment of breast cancer. …
Metadata
Title
Controversies in Breast Cancer 2009
Author
William R Miller
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 3/2009
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2420

Other articles of this Special Issue 3/2009

Breast Cancer Research 3/2009 Go to the issue

Section introduction

Who would have thought it! Influence on outcome of radiotherapy, Ki67 and stroma. Introduction to Session 5

Short communication

The role of preclinical animal models in breast cancer drug development

Short communication

Mammographic density

Short communication

Next-generation sequencing

Section introduction

Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8

Short communication

Breast screening has increased the number of mastectomies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits